|
|
Chemdea |
|
PD173074 – FGF/VEGF
Receptor Tyrosine Kinase Inhibitor |
Catalog # CD0172 |
|
Price: 1 mg - $15;
5 mg - $37; 10 mg - $62; 25 mg - $125; 50 mg - $183; 100 mg - $287; 200 mg - $514; 250 mg -
$617, 500 mg - $1109, 1 g - $1994 |
Availability: In stock |
|
1-t-Butyl-3-(6-(3,5-dimethoxyphenyl)-2-(4-diethylaminobutylamino)-pyrido[2,3-d]pyrimidin-7-yl)urea
Yellow solid. PROTECT FROM LIGHT. PACKAGED UNDER INERT GAS. Purity: 99% by HPLC. CAS# 219580-11-7. Solubility: DMSO (100 mg/mL). Molecular Formula: C28H41N7O3. Molecular Weight: 523.7.
A cell-permeable pyridopyrimidine compound that acts as a potent, ATP-competitive, and reversible inhibitor of FGF and VEGF receptors (IC50 = 21.5 nM for FGFR1). It inhibits PDGFR and c-Src only at much higher concentration (IC50 = 17.6 µM, 19.8 µM, respectively) and exhibits little effect against EGFR, InsR, MEK, and cPKC even at concentrations as high as 50 µM. Shown to inhibit the autophosphorylation of endogenous FGFR1 (IC50 <5 nM) and overexpressed VEGFR2 (IC50 <200 nM) in NIH3T3 cells in vitro, and FGF- and VEGF-induced angiogenesis in mice in vivo.
References: 1. Kunath, T., et al. Development 2007, 134, 2895; 2. Stavridis, M.P., et al. Development 2007, 134, 2889; 3. Zaragosi, L.E., et al. Stem Cells 2006, 24, 2412; 4. St. Bernard, R., et al. Endocrinology 2005, 146, 1145; 5. Koziczak, M., et al. Oncogene 2004, 23, 3501; 6. Trudel, S., et al. Blood 2004, 103, 3521; 7. Skaper, S.D., et al. J. Neurochem. 2000, 75, 1520; 8. Mohammadi, M., et al. EMBO J. 1998, 17, 5896. |
|
SAME PRODUCT AS: |
||
|
Cat. No.
BV-1675-1 |
Cat. No. 13032 |
Cat. No. N/A |
|
Cat. No. 341607 |
Cat. No.
3044 |
Cat. No. P2499 |
|
CHEMDEA; 38 E Ridgewood Ave.; Suite 240; Ridgewood, NJ 07450; USA |